Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics that completed its SPAC merger in December 2018 through Avista Healthcare Public Acquisition Corp, a blank-check vehicle sponsored by Avista Capital Partners. The company, which operates in the healthcare and medical technology sector, has been publicly traded since that transaction and continues to file periodic reports with the SEC, including the 8-K submitted on June 24, 2025, under accession number 0001193125-25-145767. Organogenesis remains an active post-merger registrant. For the full filing history, deal timeline, and sponsor data on ORGO and hundreds of other de-SPAC companies, sign up for complete access at SpacDesk.